Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.65 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12356432 | 0.92 | GPR119 (0.62) | GPR119GPR183CNR2KCNH2POLB | |
| SCHEMBL11956913 | 0.88 | GPR119 (0.68) | GPR119GPR183CNR2KCNH2 | |
| SCHEMBL19454550 | 0.87 | GPR119 (0.68) | GPR119GPR183CNR2KCNH2CHRM4 | |
| SCHEMBL19450515 | 0.86 | GPR119 (0.65) | GPR119GPR183CNR2KCNH2 | |
| SCHEMBL1103887 | 0.85 | GPR119 (0.64) | GPR119GPR183CNR2KCNH2CHRM4 | |
| SCHEMBL3261058 | 0.85 | GPR119 (0.60) | GPR119GPR183CNR2KCNH2 | |
| SCHEMBL19454993 | 0.85 | GPR119 (0.60) | GPR119GPR183CNR2KCNH2POLB | |
| SCHEMBL387876 | 0.84 | GPR119 (0.71) | GPR119GPR183CNR2KCNH2 | |
| SCHEMBL28725071 | 0.84 | GPR119 (0.67) | GPR119GPR183CNR2KCNH2 | |
| SCHEMBL1103886 | 0.83 | GPR119 (0.61) | GPR119GPR183KCNH2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| EP-2328867-A1 | HETEROCYCLIC GPCR AGONISTS | Prosidion Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | GPR119 1/4885GPR183 16/4885CNR2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.